Drug discovery information integration: Virtual humans for pharmacokinetics

Drug Discovery Today: BIOSILICO

Volumn 2, Issue 2, 2004, Pages 78-84

  Leahy, David E ^a  

^a CYPROTEX DISCOVERY LTD   (United Kingdom)

Author keywords

ADME Screening; Data Integration; Pharmacokinetics; Prediction; Simulation

Indexed keywords

NEW DRUG; THIOPENTAL;

COMPUTER PROGRAM; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; MATHEMATICAL MODEL; PHARMACOKINETICS; PREDICTION; PRODUCTIVITY; REVIEW; SIMULATION;

EID: 12344297509     PISSN: 17418364     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1741-8364(04)02394-7     Document Type: Review

References (58)

1. Teorell T. Kinetics of the distribution of substances administered to the body. I & II. Arch. Int. Pharmacodyn. 57:1937;202-240
2. Mapleson W.W. Circulation-time models of the uptake of inhaled anaesthetics and data for quantifying them. Br. J. Anaesth. 45:1973;319-334
3. Bellman R.R., et al. Mathematical models in chemotherapy. Fourth Berkeley Symposium on Mathematical Statistics and Probability. 1961;57-66
4. Bischoff K.B., et al. Preliminary model for methotrexate pharmacokinetics. J. Pharm. Sci. 59:1970;149-153
5. Bischoff K.B., Dedrick R.L. Thiopental pharmacokinetics. J. Pharm. Sci. 57:1968;1346-1351
6. Rowland M. Physiologic pharmacokinetic models and interspecie scaling. Rowland M., Tucker G.T. Pharmacokinetics: Theory and Methodology. 1986;69-88 Pergamon Press, Oxford
7. Rowland M. Physiologic pharmacokinetic models and interanimal species scaling. Pharmacol. Ther. 29:1985;49-68
8. Toon S., Rowland M. Structure-pharmacokinetic relationships among the barbiturates in the rat. J. Pharmacol. Exp. Ther. 225:1983;752-763
9. Sugiyama Y. Future prospects for toxicokinetics: prediction of drug disposition and adverse effects in humans from in vitro measurements of drug metabolism, transport and binding. J. Toxicol. Sci. 23:(supplement 4):1998;647-652
10. Lin J.H., et al. In vitro and in vivo evaluation of the tissue to blood partition coefficient for physiological pharmacokinetic models. J. Pharmacokinet. Biopharm. 10:1982;637-647
11. Lin J., et al. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J. Pharmacokinet. Biopharm. 10:1982;649-661
12. Yu L., Amidon G. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. 186:1999;119-125
13. Andersen M.E., et al. Physiologically based pharmacokinetic (PBPK) models for nasal tissue dosimetry of organic esters: assessing the state-of-knowledge and risk assessment applications with methyl methacrylate and vinyl acetate. Regul. Toxicol. Pharmacol. 36:2002;234-245
14. Clewell H.J., et al. Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit. Rev. Toxicol. 32:2002;329-389
15. Clewell R.A., Gearhart J.M. Pharmacokinetics of toxic chemicals in breast milk: use of PBPK models to predict infant exposure. Environ. Health Perspect. 110:2002;A333-A337
16. Leahy D.E. Progress in simulation modelling for pharmacokinetics. Curr. Top. Med. Chem. 3:2003;1257-1268
17. Grass G.M., Sinko P.J. Physiologically-based pharmacokinetic simulation modelling. Adv. Drug Deliv. Rev. 54:2002;433-451
18. Grass G.M. Simulation models to predict oral drug absorption from in vitro data. Adv. Drug Deliv. Rev. 23:1997;199-219
19. Rowland, M. et al. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report: 2002 May 29-30; Georgetown, WA. AAPS Pharm Sci; 2004: in press
20. Lesko L.J., et al. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Eur. J. Pharm. Sci. 10:2000;iv-xiv
21. Peck C.C., et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J. Clin. Pharmacol. 34:1994;111-119
22. Gerlowski L.E., Jain R.K. Physiologically based pharmacokinetic modeling: principles and applications. J. Pharm. Sci. 72:1983;1103-1127
23. Hoang K-C.T. Physiologically based pharmacokinetic models: mathematical fundamentals and simulation implementations. Toxicol. Lett. 79:1995;99-106
24. Nestorov I.A., et al. Lumping of whole-body physiologically based pharmacokinetic models. J. Pharmacokinet. Biopharm. 26:1998;21-46
25. Poulin P., Theil F.P. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci. 91:2002;1358-1370
26. Ritschel W.A., Hammer G.V. Prediction of the volume of distribution from in vitro data and use for estimating the absolute extent of absorption. Int. J. Clin. Pharmacol. Ther. Toxicol. 18:1980;298-316
27. Lombardo F., et al. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J. Med. Chem. 45:2002;2867-2876
28. Nestorov I., et al. Quantitative structure-pharmacokinetics relationships: II. A mechanistically based model to evaluate the relationship between tissue distribution parameters and compound lipophilicity. J. Pharmacokinet. Biopharm. 26:1998;521-545
29. Paterson S., Mackay D. Correlation of tissue, blood, and air partition coefficients of volatile organic chemicals. Br. J. Ind. Med. 46:1989;321-328
30. Perbellini L., et al. Partition coefficients of some industrial aliphatic hydrocarbons (C5-C7) in blood and human tissues. Br. J. Ind. Med. 42:1985;162-167
31. Albanese R.A., et al. Physiologically based pharmacokinetic models for the transport of trichloroethylene in adipose tissue. Bull. Math. Biol. 64:2002;97-131
32. Tan Y.M., et al. Biologically motivated computational modeling of chloroform cytolethality and regenerative cellular proliferation. Toxicol. Sci. 75:2003;192-200
33. Dennison J.E., et al. Characterization of the pharmacokinetics of gasoline using PBPK modeling with a complex mixtures chemical lumping approach. Inhal. Toxicol. 15:2003;961-986
34. Thrall K., Woodstock A. Evaluation of the dermal bioavailability of aqueous xylene in F344 rats and human volunteers. J. Toxicol. Environ. Health A. 66:2003;1267-1281
35. Lipscomb J.C., et al. The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans. Risk Anal. 23:2003;1221-1238
36. Price P.S., et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 33:2003;469-503
37. Sarangapani R., et al. Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. Inhal. Toxicol. 15:2003;987-1016
38. Li J., Gwilt P.R. The effect of age on the early disposition of doxorubicin. Cancer Chemother. Pharmacol. 51:2003;395-402
39. Price K., et al. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J. Toxicol. Environ. Health A. 66:2003;417-433
40. Blesch K.S., et al. Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience. Invest. New Drugs. 21:2003;195-223
41. Theil F.P., et al. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol. Lett. 138:2003;29-49
42. Nestorov I. Whole body pharmacokinetic models. Clin. Pharmacokinet. 42:2003;883-908
43. Klein M.T., et al. BioMOL: a computer-assisted biological modeling tool for complex chemical mixtures and biological processes at the molecular level. Environ. Health Perspect. 110:(supplement 6):2002;1025-1029
44. Kerns E.H. High throughput physicochemical profiling for drug discovery. J. Pharm. Sci. 90:2001;1838-1858
45. Chen T.M., et al. Evaluation of a method for high throughput solubility determination using a multi-wavelength UV plate reader. Comb. Chem. High Throughput Screen. 5:2002;575-581
46. Bevan C.D., Lloyd R.S. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal. Chem. 72:2000;1781-1787
47. Box K., et al. High-throughput measurement of pKa values in a mixed-buffer linear pH gradient system. Anal. Chem. 75:2003;883-892
48. Avdeef A. pH-metric log P. II: Refinement of partition coefficients and ionization constants of multiprotic substances. J. Pharm. Sci. 82:1993;183-190
49. Valko K., et al. Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: comparison with other lipophilicity measures. J. Pharm. Sci. 89:2000;1085-1096
50. Curtis C.G., et al. Organ perfusion and mass spectrometry: a timely merger for drug development. Curr. Top. Med. Chem. 2:2002;77-86
51. Chang T.K., et al. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 7:1997;211-221
52. Ekins S., et al. Progress in predicting human ADME parameters in silico. J. Pharmacol. Toxicol. Methods. 44:2000;251-272
53. Ekins S., Wrighton S.A. Application of in silico approaches to predicting drug-drug interactions. J. Pharmacol. Toxicol. Methods. 45:2001;65-69
54. Ekins S., Rose J. In silico ADME/Tox: the state of the art. J. Mol. Graph. Model. 20:2002;305-309
55. van de Waterbeemd H. High-throughput and in silico techniques in drug metabolism and pharmacokinetics. Curr. Opin. Drug Discov. Dev. 5:2002;33-43
56. van de Waterbeemd H., Gifford E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. 2:2003;192-204
57. van de Waterbeemd H., Jones B.C. Predicting oral absorption and bioavailability. Prog. Med. Chem. 41:2003;1-59
58. Agrafiotis D.K., Xu H. A geodesic framework for analyzing molecular similarities. J. Chem. Inf. Comput. Sci. 43:2003;475-484